CompletedPhase 2ACTRN12609000674235

Trial of swine influenza vaccine in healthy adults

A randomised, controlled, study in healthy adults to evaluate the safety and immunogenicity of an adjuvanted recombinant 2009 H1N1 pandemic swine influenza vaccine

Sponsor

Vaxine Pty Ltd

Enrollment

300 participants

Start Date

Jul 20, 2009

Study Type

Interventional

Conditions

Swine influenza

Summary

This is the first human study of a novel swine flu vaccine that is designed to identify the optimum dose of vaccine, the optimum number of doses and whether or not an adjuvant is required to provide maximal protection against swine flu

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 70 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a swine influenza (flu) vaccine in healthy adults aged 18 to 70. The goal is to see how safe and effective the vaccine is. People who are pregnant or breastfeeding cannot take part.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Recombinant 2009 H1 haemagglutinin in Advax-adjuvanted vaccine -Subjects will be randomised to receive one of three doses of haemagglutinin ranging from 5, 15 and 45 micrograms

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12609000674235